Literature DB >> 15887111

Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitis.

Lisa M DiFedele1, Jiman He, Erin L Bonkowski, Xiaonan Han, Matthew A Held, Alan Bohan, Ram K Menon, Lee A Denson.   

Abstract

BACKGROUND & AIMS: Cytokines including tumor necrosis factor alpha (TNFalpha) may create a state of growth hormone (GH) resistance in Crohn's disease. Anabolic effects of GH are mediated via phosphorylation of the signal transducer and activator of transcription (STAT)5b transcription factor. Although GH resistance in other settings has been linked to a defect in janus kinase-STAT signaling, the molecular basis for GH resistance in colitis was not known. We hypothesized that the GH-induced phosphorylation of STAT5b would be impaired in colitis, and that TNFalpha blockade would restore GH signaling.
METHODS: Growth, body composition, and molecular regulators of GH signaling were determined in interleukin-10 null mice with chronic colitis and wild-type controls, +/- treatment with an anti-TNFalpha antibody.
RESULTS: Interleukin-10 null mice exhibited significant alterations in growth, body composition, and feed efficiency. Liver insulin-like growth factor 1 expression was reduced in colitic mice. This was associated with down-regulation of GH receptor (GHR) expression and impaired GH-dependent STAT5b activation. Down-regulation of GHR expression was associated with reduced nuclear abundance and DNA binding of the GHR gene-promoter transactivator, Sp3. TNFalpha down-regulated GHR abundance and prevented GH-induced tyrosine phosphorylation of STAT5 in rat hepatocytes in culture. TNFalpha neutralization up-regulated liver GHR abundance and restored GH activation of STAT5 and serum insulin-like growth factor 1 levels in colitic mice; this preceded improvements in weight gain and disease activity.
CONCLUSIONS: GH resistance in experimental colitis is caused by down-regulation of GHR expression, thereby reducing GH-dependent STAT5 activation. TNFalpha blockade restores liver GH signaling and improves anabolic metabolism in this setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15887111     DOI: 10.1053/j.gastro.2005.02.003

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

1.  Sex differences in statural growth impairment in Crohn's disease: role of IGF-1.

Authors:  Neera Gupta; Robert H Lustig; Michael A Kohn; Marjorie McCracken; Eric Vittinghoff
Journal:  Inflamm Bowel Dis       Date:  2011-02-01       Impact factor: 5.325

2.  ECM1 is an essential factor for the determination of M1 macrophage polarization in IBD in response to LPS stimulation.

Authors:  Yaguang Zhang; Xuezhen Li; Zhongguang Luo; Liyan Ma; Songling Zhu; Zhishuo Wang; Jing Wen; Shipeng Cheng; Wangpeng Gu; Qiaoshi Lian; Xinhao Zhao; Weiguo Fan; Zhiyang Ling; Jing Ye; Songguo Zheng; Dangsheng Li; Hongyan Wang; Jie Liu; Bing Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-24       Impact factor: 11.205

3.  βTrCP controls GH receptor degradation via two different motifs.

Authors:  Ana C da Silva Almeida; Ger J Strous; Agnes G S H van Rossum
Journal:  Mol Endocrinol       Date:  2011-10-27

4.  Tumour necrosis factor alpha blockade induces an anti-inflammatory growth hormone signalling pathway in experimental colitis.

Authors:  X Han; N Benight; B Osuntokun; K Loesch; S J Frank; L A Denson
Journal:  Gut       Date:  2006-06-15       Impact factor: 23.059

5.  Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis.

Authors:  Xiaonan Han; Bankole Osuntokun; Nancy Benight; Kimberly Loesch; Stuart J Frank; Lee A Denson
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

Review 6.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

7.  Skeletal muscle catabolism in trinitrobenzene sulfonic acid-induced murine colitis.

Authors:  Frances Puleo; Katia Meirelles; Maithili Navaratnarajah; Leo Fitzpatrick; Margaret L Shumate; Robert N Cooney; Charles H Lang
Journal:  Metabolism       Date:  2010-05-23       Impact factor: 8.694

8.  Growth hormone prevents the development of autoimmune diabetes.

Authors:  Ricardo Villares; Dimitri Kakabadse; Yasmina Juarranz; Rosa P Gomariz; Carlos Martínez-A; Mario Mellado
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 9.  Delays in puberty, growth, and accrual of bone mineral density in pediatric Crohn's disease: despite temporal changes in disease severity, the need for monitoring remains.

Authors:  Mark D DeBoer; Lee A Denson
Journal:  J Pediatr       Date:  2013-03-22       Impact factor: 4.406

10.  Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis.

Authors:  Brad A Pasternak; Sharon D'Mello; Ingrid I Jurickova; Xiaonan Han; Tara Willson; Leah Flick; Lisa Petiniot; Naonori Uozumi; Senad Divanovic; Anna Traurnicht; Erin Bonkowski; Subra Kugathasan; Christopher L Karp; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.